Literature DB >> 24107801

Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

F Ganci1, A Sacconi, N Bossel Ben-Moshe, V Manciocco, I Sperduti, L Strigari, R Covello, M Benevolo, E Pescarmona, E Domany, P Muti, S Strano, G Spriano, G Fontemaggi, G Blandino.   

Abstract

BACKGROUND: TP53 mutation is associated with decreased survival rate in head and neck squamous cell carcinoma (HNSCC) patients. We set out to identify microRNAs (miRNAs) whose expression associates with TP53 mutation and survival in HNSCC. PATIENTS AND METHODS: We analyzed TP53 status by direct sequencing of exons 2 through 11 of a prospective series of 121 HNSCC samples and assessed its association with outcome in 109 followed-up patients. We carried out miRNA expression profiling on 121 HNSCC samples and 66 normal counterparts. miRNA associations with TP53 mutations and outcome were evaluated.
RESULTS: A TP53 mutation was present in 58% of the tumors and TP53 mutations were significantly associated with a shorter recurrence-free survival. This association was stronger in the clinical subgroup of patients subjected to adjuvant therapy after surgery. The expression of 49 miRNAs was significantly associated with TP53 status. Among these 49, we identified a group of 12 miRNAs whose expression correlates with recurrence-free survival and a group of 4 miRNAs that correlates with cancer-specific survival. The two groups share three miRNAs. Importantly, miRNAs that correlate with survival are independent prognostic factors either when considered individually or as signatures.
CONCLUSIONS: miRNAs expression associates with TP53 status and with reduced survival after surgical treatment of squamous cell carcinoma of the head and neck.

Entities:  

Keywords:  HNSCC; TP53 mutation; clinical outcome; microRNA

Mesh:

Substances:

Year:  2013        PMID: 24107801      PMCID: PMC3841017          DOI: 10.1093/annonc/mdt380

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  28 in total

Review 1.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer.

Authors:  R Erber; C Conradt; N Homann; C Enders; M Finckh; A Dietz; H Weidauer; F X Bosch
Journal:  Oncogene       Date:  1998-04-02       Impact factor: 9.867

3.  hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.

Authors:  Harriet E Gee; Carme Camps; Francesca M Buffa; Shalini Patiar; Stuart C Winter; Guy Betts; Jarrod Homer; Rogan Corbridge; Graham Cox; Catharine M L West; Jiannis Ragoussis; Adrian L Harris
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

Review 4.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 5.  Mutant p53: an oncogenic transcription factor.

Authors:  S Strano; S Dell'Orso; S Di Agostino; G Fontemaggi; A Sacchi; G Blandino
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

Review 6.  The molecular biology of head and neck cancer.

Authors:  C René Leemans; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

Review 7.  Mutant p53 proteins: between loss and gain of function.

Authors:  Sabrina Strano; Stefania Dell'Orso; Adriana Maria Mongiovi; Olimpia Monti; Eleonora Lapi; Silvia Di Agostino; Giulia Fontemaggi; Giovanni Blandino
Journal:  Head Neck       Date:  2007-05       Impact factor: 3.147

8.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

Review 9.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

10.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Authors:  M Luana Poeta; Judith Manola; Meredith A Goldwasser; Arlene Forastiere; Nicole Benoit; Joseph A Califano; John A Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M Koch
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

View more
  35 in total

1.  Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence.

Authors:  Federica Ganci; Andrea Sacconi; Valentina Manciocco; Renato Covello; Maria Benevolo; Francesca Rollo; Sabrina Strano; Sara Valsoni; Silvio Bicciato; Giuseppe Spriano; Paola Muti; Giulia Fontemaggi; Giovanni Blandino
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

2.  MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.

Authors:  Federica Lo Sardo; Mattia Forcato; Andrea Sacconi; Valeria Capaci; Francesca Zanconato; Silvia Di Agostino; Giannino Del Sal; Pier Paolo Pandolfi; Sabrina Strano; Silvio Bicciato; Giovanni Blandino
Journal:  Carcinogenesis       Date:  2016-10-17       Impact factor: 4.944

Review 3.  Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.

Authors:  Mariama El Baroudi; Jean-Pascal Machiels; Sandra Schmitz
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

4.  Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

Authors:  Marco Cordani; Elisa Oppici; Ilaria Dando; Elena Butturini; Elisa Dalla Pozza; Mercedes Nadal-Serrano; Jordi Oliver; Pilar Roca; Sofia Mariotto; Barbara Cellini; Giovanni Blandino; Marta Palmieri; Silvia Di Agostino; Massimo Donadelli
Journal:  Mol Oncol       Date:  2016-04-12       Impact factor: 6.603

Review 5.  Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.

Authors:  K Devaraja
Journal:  Pharmaceut Med       Date:  2019-08

6.  What biomarkers (if any) for precise medicine?

Authors:  Sabrina Strano; Paola Muti; Giovanni Blandino
Journal:  Aging (Albany NY)       Date:  2015-08       Impact factor: 5.682

7.  Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.

Authors:  Fabio Valenti; Federica Ganci; Giulia Fontemaggi; Andrea Sacconi; Sabrina Strano; Giovanni Blandino; Silvia Di Agostino
Journal:  Oncotarget       Date:  2015-03-20

8.  microRNAs: short non-coding bullets of gain of function mutant p53 proteins.

Authors:  Sara Donzelli; Sabrina Strano; Giovanni Blandino
Journal:  Oncoscience       Date:  2014-06-07

Review 9.  Oncogenic MicroRNAs: Key Players in Malignant Transformation.

Authors:  Tania Frixa; Sara Donzelli; Giovanni Blandino
Journal:  Cancers (Basel)       Date:  2015-12-18       Impact factor: 6.639

10.  Epigenetic silencing of miR-145-5p contributes to brain metastasis.

Authors:  Sara Donzelli; Federica Mori; Teresa Bellissimo; Andrea Sacconi; Beatrice Casini; Tania Frixa; Giuseppe Roscilli; Luigi Aurisicchio; Francesco Facciolo; Alfredo Pompili; Maria Antonia Carosi; Edoardo Pescarmona; Oreste Segatto; Greg Pond; Paola Muti; Stefano Telera; Sabrina Strano; Yosef Yarden; Giovanni Blandino
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.